Naloxazone
From Self-sufficiency
| Naloxazone | |
|---|---|
| File:Naloxazone.png | |
| (5α)- 17-allyl- 3,14-dihydroxy- 4,5-epoxymorphinan- 6-one hydrazone | |
| Other names Naloxone- 6-hydrazone | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 73674-85-8 |
| PubChem | 9576788 |
| SMILES | Script error: No such module "collapsible list". |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C19H23N3O3 |
| Molar mass | 341.4 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Naloxazone is an irreversible μ opioid receptor antagonist which is selective for the μ1 receptor subtype.[1] Naloxazone produces very long lasting antagonist effects as it forms a covalent bond to the active site of the mu-opioid receptor,[2] thus making it impossible for the molecule to unbind and blocking the receptor permanently until the receptor is recycled by endocytosis.
See also
- Chlornaltrexamine, an irreversible mixed agonist-antagonist
- Oxymorphazone, an irreversible μ-opioid full agonist
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
- ↑ Pasternak GW, Childers SR, Snyder SH. "Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors." Science. 1980 May 2; 208(4443):514-6. PMID 6245448. doi:10.1126/science.6245448
- ↑ Ling GS, Simantov R, Clark JA, Pasternak GW. Naloxonazine actions in vivo. European Journal of Pharmacology. 1986 Sep 23;129(1-2):33-8. PMID 3021478
